Department of Obstetrics and Gynecology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
J Clin Pathol. 2012 Feb;65(2):117-21. doi: 10.1136/jclinpath-2011-200362. Epub 2011 Oct 19.
The p16(INK4A) protein (p16) is a cyclin-dependent kinase inhibitor that arrests the cell cycle in the G1 phase.
To explore the potential of p16 as a predictive marker for lymph node (LN) metastasis and prognosis in cervical carcinomas.
145 patients diagnosed with FIGO stage I to IV cervical carcinoma were studied; 95 underwent LN dissection. The expression of p16 protein was studied by immunohistochemistry using tissue microarrays.
Overexpression of p16 was seen in 108 of 145 (74.5%) invasive carcinomas. There was a significant correlation between p16 expression and LN metastasis (p=0.007). Patients with p16 overexpression had poorer survival than patients with p16 underexpression (59.3% vs 83.8% 5-year survival rate, log-rank p=0.015). In univariate analysis, p16 expression was a significant predictor of survival (RR 2.76, p=0.02).
Results suggest that p16 expression is an important predictive factor of LN metastasis in cervical cancer patients. Moreover, p16 overexpression is associated with a poor prognosis. Therefore, immunohistochemical evaluation of p16 expression is of potential value for treatment planning in cervical carcinomas.
p16（INK4A）蛋白（p16）是一种细胞周期蛋白依赖性激酶抑制剂，可使细胞周期在 G1 期停滞。
探讨 p16 作为预测宫颈癌淋巴结（LN）转移和预后的标志物的潜力。
研究了 145 例诊断为 FIGO Ⅰ至Ⅳ期宫颈癌的患者；其中 95 例行 LN 解剖。使用组织微阵列通过免疫组织化学研究 p16 蛋白的表达。
在 145 例浸润性癌中，有 108 例（74.5%）出现 p16 过表达。p16 表达与 LN 转移之间存在显著相关性（p=0.007）。p16 过表达的患者比 p16 低表达的患者生存率差（5 年生存率分别为 59.3%和 83.8%，log-rank p=0.015）。在单因素分析中，p16 表达是生存的显著预测因子（RR 2.76，p=0.02）。
结果表明，p16 表达是宫颈癌患者 LN 转移的重要预测因素。此外，p16 过表达与预后不良相关。因此，p16 表达的免疫组织化学评估对宫颈癌的治疗计划具有潜在价值。
